MA55857A - Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations - Google Patents

Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations

Info

Publication number
MA55857A
MA55857A MA055857A MA55857A MA55857A MA 55857 A MA55857 A MA 55857A MA 055857 A MA055857 A MA 055857A MA 55857 A MA55857 A MA 55857A MA 55857 A MA55857 A MA 55857A
Authority
MA
Morocco
Prior art keywords
nutraceutic
vitamins
pyrimidine
preparation
dosage forms
Prior art date
Application number
MA055857A
Other languages
English (en)
Inventor
Mollar Berta Fernández
Sáiz Pablo Martín
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MA55857A publication Critical patent/MA55857A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
MA055857A 2019-05-06 2019-11-06 Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations MA55857A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382340 2019-05-06

Publications (1)

Publication Number Publication Date
MA55857A true MA55857A (fr) 2022-03-16

Family

ID=66529933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055857A MA55857A (fr) 2019-05-06 2019-11-06 Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations

Country Status (21)

Country Link
US (1) US20220160744A1 (fr)
EP (1) EP3965744A1 (fr)
JP (1) JP2022531663A (fr)
KR (1) KR20220005024A (fr)
CN (1) CN113784706B (fr)
AU (1) AU2019444412A1 (fr)
BR (1) BR112021021769A2 (fr)
CA (1) CA3137221A1 (fr)
CL (1) CL2021002874A1 (fr)
CO (1) CO2021015353A2 (fr)
DO (1) DOP2021000225A (fr)
EA (1) EA202193041A1 (fr)
EC (1) ECSP21080548A (fr)
JO (1) JOP20210296A1 (fr)
MA (1) MA55857A (fr)
MX (1) MX2021013565A (fr)
PE (1) PE20220498A1 (fr)
SG (1) SG11202111084WA (fr)
TW (1) TWI827736B (fr)
UA (1) UA127913C2 (fr)
WO (1) WO2020224795A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1363398A (en) * 1973-03-29 1974-08-14 Yamasa Shoyu Kk Uridine-5.-monophosphate compositions
CA995133A (en) * 1973-03-29 1976-08-17 Shunkichi Tamura Uridine-5'-monophosphate compositions
JPH01308232A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 固型医薬およびその製造法
JPH05194275A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 製剤用組成物、固形製剤および薬物の防臭方法
DE10215753A1 (de) * 2002-04-10 2003-10-30 Trommsdorff Arzneimittel Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems
JP4775879B2 (ja) * 2004-11-17 2011-09-21 塩野義製薬株式会社 ビタミン組成物
JP5032310B2 (ja) * 2005-05-27 2012-09-26 興和株式会社 疲労回復のための医薬
KR100869444B1 (ko) * 2007-07-11 2008-11-18 주식회사 중외제약 유비데카레논을 함유하는 다층정 비타민 복합제제
WO2012091542A1 (fr) * 2010-12-28 2012-07-05 N.V. Nutricia Combinaison de composants destinée à prévenir et traiter la fragilité
WO2012125020A1 (fr) * 2011-03-14 2012-09-20 N.V. Nutricia Méthode de traitement d'un traumatisme neurologique
WO2016148561A1 (fr) * 2015-03-16 2016-09-22 N.V. Nutricia Procédé d'amélioration de la fonction vésicale
US11291683B2 (en) * 2016-04-01 2022-04-05 Access Business Group International Llc Bilayer tablets of B vitamins and process for preparing the same
EP3366291A1 (fr) * 2017-02-22 2018-08-29 Montero Gida Sanayi Ve Ticaret A.S. Compositions pharmaceutiques orales solides comprenant de l'acide lipoïque alpha et des vitamines solubles dans l'eau

Also Published As

Publication number Publication date
JOP20210296A1 (ar) 2023-01-30
EP3965744A1 (fr) 2022-03-16
BR112021021769A2 (pt) 2021-12-28
PE20220498A1 (es) 2022-04-07
WO2020224795A1 (fr) 2020-11-12
UA127913C2 (uk) 2024-02-07
AU2019444412A1 (en) 2021-11-04
DOP2021000225A (es) 2022-03-15
CN113784706A (zh) 2021-12-10
CN113784706B (zh) 2024-01-05
CO2021015353A2 (es) 2021-11-19
ECSP21080548A (es) 2022-02-25
TWI827736B (zh) 2024-01-01
JP2022531663A (ja) 2022-07-08
US20220160744A1 (en) 2022-05-26
CA3137221A1 (fr) 2020-11-12
KR20220005024A (ko) 2022-01-12
EA202193041A1 (ru) 2022-02-10
CL2021002874A1 (es) 2022-06-17
TW202108132A (zh) 2021-03-01
SG11202111084WA (en) 2021-11-29
MX2021013565A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
Ajani et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
Ntaios et al. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201100032A1 (ru) Соединения пиридина
BR112018006817A2 (pt) método de tratamento do câncer
Mustafa et al. Varicella zoster virus: review of its management
MX2018008754A (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
WO2008071573A3 (fr) Préparation en poudre du valganciclovir
IL284930A (en) History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
MA45625A (fr) Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
MA55857A (fr) Formes posologiques solides pharmaceutiques ou nutraceutiques multicouches comprenant des dérivés de pyrimidine et/ou de purine et des vitamines b, leur préparation et leurs utilisations
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
Ross et al. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis
BR112019005214A2 (pt) composição farmacêutica compreendendo antagonista do receptor de mineralocorticoide e uso da mesma
JP2016501222A5 (fr)
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
SI2914599T1 (en) The solid salt form as alpha-6-mPEG6-O-hydroxycodone as opioid agonists and its use
WO2017067664A9 (fr) Composés oxa-diazaspiro ayant une activité contre la douleur
BR112016002194A2 (pt) “potencialização do efeito do metotrexato por meio do uso combinado com estatinas lipofílicas”
Qin et al. Reply to S. Zhang, L. Fornaro et al, and HJ Lee et al